TABLE 1.
Methods used to detect HCV RNAa
| Methodb | No. (%) of data sets
|
|
|---|---|---|
| Panel 1 | Panel 2 | |
| Qualitative | ||
| Roche Cobas/Amplicor | 7 (16) | 34 (45) |
| Roche Amplicor (manual) | 21 (47) | 16 (21) |
| Roche (details unknown) | 2 (3) | |
| In-house nested RT-PCR | 5 (11) | 13 (17) |
| In-house RT-PCR | 9 (20) | 7c (9) |
| Inno-Lipad | 2 (4) | 2 (3) |
| Unknown methodd | 1 (2) | 1 (1) |
| Total | 45 | 75 |
| Quantitative | ||
| Roche Cobas/Amplicor | 7 (20) | 24 (50) |
| Roche Amplicor (manual) | 16 (46) | 10 (21) |
| Bayer bDNA version 2.0 | 8 (23) | 11 (23) |
| BAG/AcuGen | 1 (3) | 1 (2) |
| In-house RT-PCR | 2 (6) | |
| In-house RT-PCR (Taqman) | 1 (3) | 1 (2) |
| In-house RT-PCR (Light Cycler) | 1 (2) | |
| Total | 35 | 48 |
a
Some laboratories submitted more than one data set.
b
Laboratories using Roche assays often provided no further details on the precise version of the test and whether they used manual or automated systems.
c
Additional HCV genotyping was performed for one of these data sets.
d
Additional HCV genotyping was performed on all of these data sets.